Podcast Episodes
Back to Search
ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck
At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines an…
1 month, 1 week ago
France’s biotech ecosystem: science, capital and scale
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing from Ksenija Pavletic, part…
1 month, 1 week ago
Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds
Eli Lilly has been as acquisitive as ever, striking five new deals in the past week alone. On Tuesday, the company dove into the deep end of vaccine …
1 month, 1 week ago
Inside Germany’s biotech capital infrastructure and innovation engine
In this episode of Denatured, as part of our series of the European life science investment ecosystem, you'll be hearing from Regina Hodits, managin…
1 month, 2 weeks ago
FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
FDA Commissioner Marty Makary officially resigned last week following reports of his ouster. Then, the acting directors for the agency’s two main rev…
1 month, 2 weeks ago
From MSCs to iPSCs: building the cell therapy future
In this episode of Denatured, you'll be hearing from Miguel Forte, president of the International Society for Cell and Gene Therapy (ISCT), and John …
1 month, 3 weeks ago
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
Moments after recording this episode of The Weekly, FDA Commissioner Marty Makary announced his resignation. Reports first circulated last Friday tha…
1 month, 3 weeks ago
Fibrosis, IPF and the search for better therapies
In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder & Chief Medical Office…
2 months ago
Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening
First quarter earnings continue to roll in, with Pfizer, Eli Lilly, Amgen and more reporting in the past week. While Pfizer beat consensus estimates,…
2 months ago
Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening
First quarter earnings continue to roll in, with Pfizer, Eli Lilly, Amgen and more reporting in the past week. While Pfizer beat consensus estimates,…
2 months ago